Global asthma market to hit $18 billion by 2021 boosted by biologics

14 August 2014
datamonitor-healthcare-big

The market for asthma drugs is predicted to reach $18 billion by 2021, according to new research from analyst firm Datamonitor Healthcare.

With six products forecast to launch, the research estimates the asthma market in the USA, Japan, and five major European Union markets (France, Germany, Italy, Spain and the UK), will grow at a rate of 1.4% by 2021.

It predicts that two key marketed drugs, UK pharma major GlaxoSmithKline’s (LSE: GSK) Advair (fluticasone/salmeterol) and Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) Symbicort (budesonide/formoterol), will face erosion of sales due to the arrival of GSK’s Breo (fluticasone/vilanterol), as well as from generics emerging from the pipeline.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical